NAV

Valomaciclovir stearate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Valomaciclovir stearate
DrugBank Accession Number
DB15651
Background

Valomaciclovir stearate is under investigation in clinical trial NCT00831103 (A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster).

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 618.864
Monoisotopic: 618.446868992
Chemical Formula
C33H58N6O5
Synonyms
  • Valomaciclovir stearate
External IDs
  • A 174606.0
  • A-174606.0
  • ABT-606
  • EPB 348
  • MIV 606
  • MIV-606

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
506LI1B3A3
CAS number
195156-77-5
InChI Key
ACBSZTQIFTYFGH-IAPPQJPRSA-N
InChI
InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1
IUPAC Name
(2R)-4-{[(2S)-2-amino-3-methylbutanoyl]oxy}-2-[(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)methyl]butyl octadecanoate
SMILES
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CCOC(=O)[C@@H](N)C(C)C)CN1C=NC2=C1N=C(N)NC2=O

References

General References
Not Available
ChemSpider
2300861
ChEMBL
CHEMBL2105845
ZINC
ZINC000008214706

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentHerpes Zoster1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000371 mg/mLALOGPS
logP5.92ALOGPS
logP6.72Chemaxon
logS-6.2ALOGPS
pKa (Strongest Acidic)10.17Chemaxon
pKa (Strongest Basic)7.48Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area163.92 Å2Chemaxon
Rotatable Bond Count27Chemaxon
Refractivity173.82 m3·mol-1Chemaxon
Polarizability74.49 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at March 31, 2020 21:32 / Updated at February 21, 2021 18:55